Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs Kina

Two GLP-1 providers, one scoreboard. We put CoreAge Rx and Kina head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 176 · Grade C

Kina

Visit Kina Full brief →

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 69 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.

That doesn't make Kina a bad call — it's best for women seeking midlife-focused clinical support who can confirm the medication, complete bill and applicable cancellation terms. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
48
Supply Reliability
95
84
Transparency
90
72
Access Breadth
93
50
Clinical Oversight
92
88
Track Record
88
80
CoreAge RxBrief Score 94 · 69Kina

Price, coverage & the tracker

CoreAge RxKina
Brief Score94/100 (A)69/100 (C)
Semaglutide

From $79/mo

Annual offer: 12 months paid upfront, from $948.

Main site: from $99/mo; confirm the selected offer.

Full price details

From $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo

Confirm medication + care total

Injection advertised at $199/mo ongoing. The no-membership offer conflicts with separate-fee language in general terms.

Full price details

Compounded semaglutide offered; complete quote unknown because membership terms conflict; injection advertised $199/month ongoing; earlier listing: From $179/mo (starting dose, plus a separate fee, compounded)

Tirzepatide

From $129/mo

Annual offer: 12 months paid upfront, from $1,548.

Main site: from $149/mo; confirm the selected offer.

Full price details

From $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo

Confirm medication + care total

Injection advertised at $249/mo ongoing. The no-membership offer conflicts with separate-fee language in general terms.

Full price details

Compounded tirzepatide offered; complete quote unknown because membership terms conflict; injection advertised $249/month ongoing; earlier listing: From $179/mo (starting dose, compounded)

CoverageUS only; restrictions by state, confirmed at intakeCare depends on clinician and pharmacy licensing in your location; no complete current state roster established
Brand-name accessNot confirmedNot confirmed
Oral / sublingualInjection onlyYes
On the trackerStableprice stableNewnew to the tracker, no prior reading

CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.

Kina: Ongoing injections list $199 semaglutide/$249 tirzepatide. Complete totals remain unconfirmed because general terms describe membership and separately billed medication.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.